HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome - Revision history

Bailey.Glen at 17:26, 3 July 2025

2025-07-03T17:26:32Z

← Older revision		Revision as of 12:26, 3 July 2025
Line 39:		Line 39:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:46, 25 May 2025

2025-05-25T21:46:03Z

← Older revision		Revision as of 16:46, 25 May 2025
Line 194:		Line 194:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 285:		Line 285:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 329:		Line 329:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:22, 25 May 2025

2025-05-25T20:22:20Z

← Older revision		Revision as of 15:22, 25 May 2025
Line 54:		Line 54:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|For POEMS syndrome: osteosclerotic myeloma
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:44, 24 March 2025

2025-03-24T17:44:02Z

← Older revision		Revision as of 12:44, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Plasma cell neoplasms with associated paraneoplastic syndrome}}		{{DISPLAYTITLE:Plasma cell neoplasms with associated paraneoplastic syndrome}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 18:		Line 17:

	Tharanga Niroshini Senaratne, PhD		Tharanga Niroshini Senaratne, PhD

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T21:43:44Z

Removed old template contents

Show changes

Bailey.Glen at 18:57, 10 February 2025

2025-02-10T18:57:36Z

Show changes

Bailey.Glen at 18:29, 10 February 2025

2025-02-10T18:29:30Z

← Older revision		Revision as of 13:29, 10 February 2025
Line 76:		Line 76:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>

	As mentioned earlier, POEMS syndrome is a rare disorder which comprises of constellation of clinical presentations with neuropathy present in almost 100% of the cases. Following are the clinical features:		As mentioned earlier, POEMS syndrome is a rare disorder which comprises of constellation of clinical presentations with neuropathy present in almost 100% of the cases. Following are the clinical features:
Line 92:		Line 92:
	*'''<u>Specific findings in Females</u>'''- amenorrhea and galactorrhea have been reported in female patients with POEMS syndrome		*'''<u>Specific findings in Females</u>'''- amenorrhea and galactorrhea have been reported in female patients with POEMS syndrome

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 133:		Line 136:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Plasma cells in BM biopsy ranges from<5% to 60%. 95% of the cases have value <5%.<ref name=":6">{{Cite journal\|last=Dispenzieri\|first=Angela\|date=2012-06-14\|title=How I treat POEMS syndrome\|url=https://doi.org/10.1182/blood-2012-03-378992\|journal=Blood\|volume=119\|issue=24\|pages=5650–5658\|doi=10.1182/blood-2012-03-378992\|issn=0006-4971\|pmc=PMC3425020\|pmid=22547581}}</ref> Usually there are a combination of normal polyclonal plasma cells and monoclonal plasma cells. The monoclonal plasma cells stains positive for λ chains (IgA and IgG). <ref>{{Cite journal\|last=Dao\|first=Linda N.\|last2=Hanson\|first2=Curtis A.\|last3=Dispenzieri\|first3=Angela\|last4=Morice\|first4=William G.\|last5=Kurtin\|first5=Paul J.\|last6=Hoyer\|first6=James D.\|date=2011-06-16\|title=Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients\|url=https://doi.org/10.1182/blood-2010-11-316935\|journal=Blood\|volume=117\|issue=24\|pages=6438–6444\|doi=10.1182/blood-2010-11-316935\|issn=0006-4971\|pmc=PMC3123015\|pmid=21385854}}</ref>		Plasma cells in BM biopsy ranges from<5% to 60%. 95% of the cases have value <5%.<ref name=":6">{{Cite journal\|last=Dispenzieri\|first=Angela\|date=2012-06-14\|title=How I treat POEMS syndrome\|url=https://doi.org/10.1182/blood-2012-03-378992\|journal=Blood\|volume=119\|issue=24\|pages=5650–5658\|doi=10.1182/blood-2012-03-378992\|issn=0006-4971\|pmc=PMC3425020\|pmid=22547581}}</ref> Usually there are a combination of normal polyclonal plasma cells and monoclonal plasma cells. The monoclonal plasma cells stains positive for λ chains (IgA and IgG). <ref>{{Cite journal\|last=Dao\|first=Linda N.\|last2=Hanson\|first2=Curtis A.\|last3=Dispenzieri\|first3=Angela\|last4=Morice\|first4=William G.\|last5=Kurtin\|first5=Paul J.\|last6=Hoyer\|first6=James D.\|date=2011-06-16\|title=Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients\|url=https://doi.org/10.1182/blood-2010-11-316935\|journal=Blood\|volume=117\|issue=24\|pages=6438–6444\|doi=10.1182/blood-2010-11-316935\|issn=0006-4971\|pmc=PMC3123015\|pmid=21385854}}</ref>
Line 155:		Line 158:

	<br />		<br />
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Chromosomal Rearrangements (Gene Fusions)==		==Chromosomal Rearrangements (Gene Fusions)==
Line 179:		Line 185:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>
	<br />		<br />
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>

Line 188:		Line 197:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	Diagnosis of POEMS syndrome requires meticulous search for clinical features and testing because of clinical simulation with other common conditions. Being one of the rare disease entities it can easily be missed by clinicians.		Diagnosis of POEMS syndrome requires meticulous search for clinical features and testing because of clinical simulation with other common conditions. Being one of the rare disease entities it can easily be missed by clinicians.
Line 233:		Line 242:
	*clinical improvement in effusions		*clinical improvement in effusions

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 281:		Line 293:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>
	A study conducted at Peking Union Medical college Hospital from November 2011 to June 2012 showed the following chromosomal abnormalities associated with POEMS syndrome.<ref>{{Cite journal\|last=Kang\|first=Wen-Ying\|last2=Shen\|first2=Kai-Ni\|last3=Duan\|first3=Ming-Hui\|last4=Zhang\|first4=Wei\|last5=Cao\|first5=Xin-Xin\|last6=Zhou\|first6=Dao-Bin\|last7=Li\|first7=Jian\|date=2013-12\|title=14q32 translocations and 13q14 deletions are common cytogenetic abnormalities in POEMS syndrome\|url=https://onlinelibrary.wiley.com/doi/10.1111/ejh.12189\|journal=European Journal of Haematology\|language=en\|volume=91\|issue=6\|pages=490–496\|doi=10.1111/ejh.12189}}</ref>. In this study, BM plasma cells CD138+ were collected using MACS system and then FISH technique was applied.		A study conducted at Peking Union Medical college Hospital from November 2011 to June 2012 showed the following chromosomal abnormalities associated with POEMS syndrome.<ref>{{Cite journal\|last=Kang\|first=Wen-Ying\|last2=Shen\|first2=Kai-Ni\|last3=Duan\|first3=Ming-Hui\|last4=Zhang\|first4=Wei\|last5=Cao\|first5=Xin-Xin\|last6=Zhou\|first6=Dao-Bin\|last7=Li\|first7=Jian\|date=2013-12\|title=14q32 translocations and 13q14 deletions are common cytogenetic abnormalities in POEMS syndrome\|url=https://onlinelibrary.wiley.com/doi/10.1111/ejh.12189\|journal=European Journal of Haematology\|language=en\|volume=91\|issue=6\|pages=490–496\|doi=10.1111/ejh.12189}}</ref>. In this study, BM plasma cells CD138+ were collected using MACS system and then FISH technique was applied.
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 310:		Line 322:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 334:		Line 349:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	<br />		<br />

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 373:		Line 391:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	A study was conducted in 20 patients of POEMS syndrome. The study showed 7 gene shaving recurrent somatic gene mutations involved in POEMS syndrome. It is important to know that none of the important gene mutations involved in MM such as NRAS, KRAS, BRAF, and TP53 were found in POEMS syndrome patients.<ref>{{Cite journal\|last=Nagao\|first=Yuhei\|last2=Mimura\|first2=Naoya\|last3=Takeda\|first3=June\|last4=Yoshida\|first4=Kenichi\|last5=Shiozawa\|first5=Yusuke\|last6=Oshima\|first6=Motohiko\|last7=Aoyama\|first7=Kazumasa\|last8=Saraya\|first8=Atsunori\|last9=Koide\|first9=Shuhei\|date=2019-07\|title=Genetic and transcriptional landscape of plasma cells in POEMS syndrome\|url=https://www.nature.com/articles/s41375-018-0348-x\|journal=Leukemia\|language=en\|volume=33\|issue=7\|pages=1723–1735\|doi=10.1038/s41375-018-0348-x\|issn=1476-5551}}</ref> [[HAEM4:Plasma Cell Neoplasms]]		A study was conducted in 20 patients of POEMS syndrome. The study showed 7 gene shaving recurrent somatic gene mutations involved in POEMS syndrome. It is important to know that none of the important gene mutations involved in MM such as NRAS, KRAS, BRAF, and TP53 were found in POEMS syndrome patients.<ref>{{Cite journal\|last=Nagao\|first=Yuhei\|last2=Mimura\|first2=Naoya\|last3=Takeda\|first3=June\|last4=Yoshida\|first4=Kenichi\|last5=Shiozawa\|first5=Yusuke\|last6=Oshima\|first6=Motohiko\|last7=Aoyama\|first7=Kazumasa\|last8=Saraya\|first8=Atsunori\|last9=Koide\|first9=Shuhei\|date=2019-07\|title=Genetic and transcriptional landscape of plasma cells in POEMS syndrome\|url=https://www.nature.com/articles/s41375-018-0348-x\|journal=Leukemia\|language=en\|volume=33\|issue=7\|pages=1723–1735\|doi=10.1038/s41375-018-0348-x\|issn=1476-5551}}</ref> [[HAEM4:Plasma Cell Neoplasms]]
Line 512:		Line 530:
	<br />		<br />

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 537:		Line 558:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	'''<u>PATHOGENESIS OF POEMS SYNDROME</u>'''		'''<u>PATHOGENESIS OF POEMS SYNDROME</u>'''
Line 548:		Line 569:
	*'''<u>λ Immunoglobulins</u>'''		*'''<u>λ Immunoglobulins</u>'''

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:34, 6 September 2024

2024-09-06T22:34:52Z

← Older revision		Revision as of 17:34, 6 September 2024
Line 20:		Line 20:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	~~[[HAEM4:~~Plasma ~~Cell Neoplasms~~\|Plasma ~~Cell Neoplasm]]~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub-Classification /~~ Subtype==		!Disease
			\|-
	~~[[HAEM4:~~Plasma ~~Cell Neoplasms~~ with ~~Associated Paraneoplastic Syndrome]]~~		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|B-cell lymphoid proliferations and lymphomas
			\|-
			\|Family
			\|Plasma cell neoplasms and other diseases with paraproteins
			\|-
			\|Type
			\|Plasma cell neoplasms
			\|-
			\|Subtype(s)
			\|Plasma cell neoplasms with associated paraneoplastic syndrome
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 22:08, 6 September 2024

2024-09-06T22:08:09Z

Show changes

Bailey.Glen at 19:36, 13 December 2023

2023-12-13T19:36:24Z

← Older revision		Revision as of 14:36, 13 December 2023
Line 9:		Line 9:
	Note: author needs to include POEMS, TEMPI, and look for AESOP content		Note: author needs to include POEMS, TEMPI, and look for AESOP content
	}}</blockquote>		}}</blockquote>

			<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>

	==Primary Author(s)*==		==Primary Author(s)*==